NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, announced plans for an underwritten public offering of common stock with BTIG, LLC as lead bookrunner and Lucid Capital Markets, LLC as joint bookrunning manager.
Focus on Psychiatric and Pain Treatments
The company is developing therapeutics based on its NMDA platform for central nervous system disorders. NRX-100, a preservative-free intravenous ketamine formulation, has received Fast Track Designation for treating suicidal ideation in depression, including bipolar depression. The company has filed an Abbreviated New Drug Application and initiated a New Drug Application filing for NRX-100 for this indication.
The company is also developing NRX-101, an oral formulation combining D-cycloserine and lurasidone, which has been awarded Breakthrough Therapy Designation for suicidal bipolar depression. Both candidates target conditions that create substantial unmet needs in behavioral health.
Use of Proceeds
The company intends to use net proceeds from the offering for working capital and general corporate purposes to support its growth. The shares will be offered under an effective shelf registration statement on Form S-3, which was declared effective by the SEC on December 22, 2025. Investors may obtain prospectus information from BTIG, LLC at 65 East 55th Street, New York, New York 10022 or by telephone at (212) 593-7555.
The offering is subject to market conditions and there is no assurance regarding timing or final terms.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.biospace.com/press-releases/nrx-pharmaceuticals-inc-announces-proposed-public-offering-of-common-stock